Neogen Corp (NEOG) Financial Statements
Industry: In Vitro & In Vivo Diagnostic Substances
In fiscal 2026, Neogen reported revenue of $870.4M, down 2.7% from $894.7M the year before. Net income was -$7.9M (a -0.9% net margin), or -$0.04 per diluted share. Gross margin was 46.9% and operating margin was -2.5%. Operating activities generated $83.2M of cash, leaving $31.9M of free cash flow. At fiscal year end, Neogen held $3.35B in total assets against $1.25B in total liabilities, including $185.5M of cash and equivalents.
Open the full interactive Neogen financials → Quarterly statements, key ratios, valuation history and price charts.
Neogen Key Stats
| Share Price | $11.73 |
|---|---|
| Market Cap | $2.56B |
| Revenue YoY Growth | -2.7% |
| 52-Week Range | $5.41 – $13.98 |
| Shares Outstanding | 218.1 million (basic, 2027 Q1) |
Neogen Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $468.5M | $527.2M | $822.4M | $924.2M | $894.7M | $870.4M |
| Cost of Goods Sold | $253.4M | $284.1M | $416.5M | $460.3M | $473.3M | $461.9M |
| Gross Profit | $215.1M | $243.0M | $406.0M | $463.9M | $421.4M | $408.5M |
| Operating Income | $74.2M | $58.6M | $37.5M | $58.7M | -$1.06B | -$21.6M |
| Pre-Tax Income | $75.3M | $60.2M | -$22.0M | -$14.3M | -$1.13B | -$9.0M |
| Income Tax | $14.4M | $11.9M | $828,000 | -$4.9M | -$41.1M | -$1.1M |
| Net Income | $60.9M | $48.3M | -$22.9M | -$9.4M | -$1.09B | -$7.9M |
| Diluted EPS | $0.57 | $0.45 | -$0.12 | -$0.04 | -$5.03 | -$0.04 |
Neogen Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $224.7M | $211.2M | $225.3M | $222.8M |
| Net Income | -$15.9M | -$17.0M | -$11.3M | -$11.9M |
| Diluted EPS | -$0.07 | -$0.08 | -$0.05 | -$0.05 |
Neogen Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $75.6M | $44.5M | $163.2M | $170.6M | $129.0M | $185.5M |
| Current Assets | $591.5M | $626.8M | $585.9M | $589.2M | $576.9M | $604.6M |
| Total Assets | $920.2M | $992.9M | $4.55B | $4.55B | $3.44B | $3.35B |
| Current Liabilities | $53.6M | $77.8M | $145.5M | $154.3M | $174.0M | $158.2M |
| Total Long-Term Debt | — | — | $885.4M | $1.79B | $1.78B | $1.59B |
| Total Liabilities | $79.8M | $105.6M | $1.42B | $1.40B | $1.37B | $1.25B |
| Shareholders' Equity | $840.4M | $887.4M | $3.13B | $3.14B | $2.07B | $2.09B |
Neogen Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $81.1M | $68.0M | $41.0M | $35.3M | $58.2M | $83.2M |
| Cash From Investing | -$105.6M | -$97.2M | $201.0M | -$29.3M | -$99.2M | $70.5M |
| Cash From Financing | $33.5M | $6.8M | -$118.1M | $1.9M | -$1.6M | -$99.4M |
| Free Cash Flow | $54.4M | $43.6M | -$24.7M | -$76.2M | -$46.4M | $31.9M |
Figures from Neogen's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Neogen financials page for every line item.
Neogen Company Profile
| Ticker | NEOG |
|---|---|
| Exchange | Nasdaq |
| Industry | In Vitro & In Vivo Diagnostic Substances |
| Headquarters | Lansing, Michigan |
| Incorporated in | Michigan |
| Fiscal Year End | May 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0000711377 |
Frequently Asked Questions
What was Neogen's revenue in fiscal 2026?
Neogen (NEOG) reported revenue of $870.4M for fiscal 2026.
What is Neogen's annual revenue history?
Neogen's annual revenue by fiscal year: 2021: $468.5M; 2022: $527.2M; 2023: $822.4M; 2024: $924.2M; 2025: $894.7M; 2026: $870.4M.
What was Neogen's net income in fiscal 2026?
Neogen reported net income of -$7.9M for fiscal 2026.
What was Neogen's earnings per share (EPS) in fiscal 2026?
Neogen's diluted EPS was -$0.04 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Neogen generate in fiscal 2026?
Neogen generated $31.9M of free cash flow in fiscal 2026.
What was Neogen's revenue last quarter?
In its most recent reported quarter (2027 Q1), Neogen reported revenue of $222.8M.
How much debt does Neogen have?
Neogen reported $1.59B of long-term debt, including the current portion, at the end of fiscal 2026.
How many shares of Neogen are outstanding?
Neogen reported a weighted average of 218.1 million basic shares outstanding in 2027 Q1.
What is Neogen's market cap?
Based on its latest closing price, Neogen (NEOG) has a market capitalization of about $2.56B.
When does Neogen's fiscal year end?
Neogen's fiscal year end, as registered with the SEC, is May 31.
Where is Neogen headquartered?
Neogen lists its business address in Lansing, Michigan in its SEC filings.
Neogen Competitors & Similar Companies
See all 15 In Vitro & In Vivo Diagnostic Substances companies →